Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Tara N. Fujimoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1685-9173; OpenAlex author ID A5013690559. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. Microdosimetric characterization of proton relative biological effectiveness in pancreatic ductal adenocarcinoma cell lines. Co-author DOI 10.3389/fonc.2026.1934487↗
  2. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1053/j.gastro.2022.02.024↗
  3. Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model. Co-author DOI 10.1186/s12885-022-09255-3↗
  4. Fasting Reduces Intestinal Radiotoxicity, Enabling Dose-Escalated Radiation Therapy for Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2019.06.2533↗
  5. Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-1785↗
  6. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. Co-author DOI 10.1172/jci.insight.126915↗
  7. Mitochondrial Fusion Suppresses Pancreatic Cancer Growth via Reduced Oxidative Metabolism Co-author DOI 10.2139/ssrn.3188491↗
  8. EGLN Inhibition Reduces Gastrointestinal Radiation Toxicity and Improves Survival in a Murine Model of Locally Advanced Pancreatic Cancer Co-author DOI 10.1101/195610↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Cullen M. Taniguchi · 7 shared papers, 2017–2022 · strength 0.65
  2. Albert C. Koong · 2 shared papers, 2019–2026 · strength 0.38
  3. Meifang Yu · 4 shared papers, 2018–2022 · strength 0.34
  4. Daniel Lin · 4 shared papers, 2018–2022 · strength 0.34
  5. Anirban Maitra · 4 shared papers, 2018–2022 · strength 0.34
  6. Tianyu Wang · 1 shared paper, 2026 · strength 0.30
  7. Fada Guan · 1 shared paper, 2026 · strength 0.30
  8. Abagail M. Delahoussaye · 2 shared papers, 2022 · strength 0.26
  9. Carolina J. García García · 2 shared papers, 2022 · strength 0.26
  10. Sonal Gupta · 3 shared papers, 2018–2019 · strength 0.22
  11. Eugene Jon Koay · 3 shared papers, 2018–2019 · strength 0.22
  12. Nicholas D. Nguyen · 2 shared papers, 2019–2022 · strength 0.19
  13. Marimar de la Cruz Bonilla · 2 shared papers, 2019 · strength 0.17
  14. Helen M Piwnica-Worms · 2 shared papers, 2019 · strength 0.17
  15. Ya’an Kang · 2 shared papers, 2018–2019 · strength 0.15
  16. Jason B. Fleming · 2 shared papers, 2018–2019 · strength 0.15
  17. Joseph Abi Jaoude · 1 shared paper, 2022 · strength 0.15
  18. Gabriel Oliveira Sawakuchi · 2 shared papers, 2017–2019 · strength 0.15
  19. Lauren Elizabeth Colbert · 2 shared papers, 2017–2019 · strength 0.15
  20. Emily G. Caggiano · 1 shared paper, 2022 · strength 0.12
  21. Natividad Roberto Fuentes · 1 shared paper, 2022 · strength 0.12
  22. Maria E. Monberg · 1 shared paper, 2022 · strength 0.12
  23. Jaewon James Lee · 1 shared paper, 2022 · strength 0.12
  24. Jun Zhao · 1 shared paper, 2022 · strength 0.12
  25. Vincent Bernard · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.